Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.70 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.70 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 1/20 | 0.70 |
| ▸ | MMP3 | P08254 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.69 |
| ▸ | USP2 | O75604 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL3155 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL29545414 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41884 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL2221981 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417262 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41883 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL28250743 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417256 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL8683380 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL497163 | 0.99 | TDP1 (0.69) | MMP2MMP3MMP7MMP8ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276420-B1 | DEVICE TO TREAT AN EYE HAVING AN EPITHELIUM WITH A DEFECT | JOURNEY1 INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10555804-B2 | Therapeutic device for pain management and vision | JOURNEY1, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180193133-A1 | THERAPEUTIC DEVICE FOR PAIN MANAGEMENT AND VISION | NEXIS VISION, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-1755616-B1 | Treatment of exudative retinopathy with mineralcorticoids | ADVANCED OCULAR SYSTEMS LTD (AU) | 2013-08-14 | — | — | EP | disclosed |
| US-8202840-B2 | Enhanced ocular neuroprotection and neurostimulation | MINU L.L.C. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202853-B2 | Convenience kit for eyelid treatment | OCUSOFT, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7833966-B2 | topically administering cyclosporine to an eye of an individual having loss of corneal sensation after refractive surgery on the eye under conditions of at least daily dosing intervals in a therapeutic regimen for a duration sufficient to provide an enhanced rate of restoration of corneal sensitivity | MINU L.L.C. | 2010-11-16 | — | — | US | disclosed |
| EP-2074994-A1 | Enhanced ocular neuroprotection/neurostimulation | Minu, L.L.C. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090143282-A1 | ENHANCED RECOVERY FOLLOWING OCULAR SURGERY | MINU L.L.C. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090137533-A1 | Convenience Kit for Eyelid Treatment | OCUSOFT, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20050261243-A1 | Antiprostaglandins for the treatment of ocular pathologies | MINU, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20050256081-A1 | Tetracycline derivatives for the treatment of ocular pathologies | MINU, LLC | 2005-11-17 | — | — | US | disclosed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040254629-A1 | Methods and apparatus for treatment of aneurysmal tissue | MEDTRONIC VASCULAR, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| US-5538954-A | SUCROSE OCTA-O-SULFONIC ACID SALTS OF TETRACYCLINES FOR INHIBITING PROTEIN SYNTHESIS | A/S DUMEX (DUMEX LTD.) (DK) | 1996-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | IL1R1, TNF, IL1A | MMP7 1102/4885MMP8 320/4885MMP13 1074/4885 |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | CCL11, SSB, TNF | MMP7 477/4885MMP8 44/4885MMP13 210/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | MMP7 1102/4885MMP8 2653/4885MMP13 1306/4885 |
| US-20050245497-A1 | Treatment of ophthalmic conditions | MC2R, NR3C2, PTGIR | MMP7 574/4885MMP8 279/4885MMP13 270/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | MMP7 2597/4885MMP8 3576/4885MMP13 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.